The current goal of Professor Teesalu’s team is to develop a TPP platform for a delivery of co-administered drugs to the deadliest brain tumor – glioblastoma. This high-grade glioma is a target that is particularly evasive. The peptides that are being developed will be able to penetrate gliomas (and potentially other tumors) independent of their angiogenic status, and to deliver drugs to infiltrating malignant cells far from the bulk glioma lesion.
The team is now characterizing, validating, and optimizing the said platform for the enhanced glioma delivery of co-injected drugs. These studies will provide the preclinical data needed to advance the glioma-specific TPP combination therapy to GLP toxicology and subsequent IND filing.
The European Research Council (ERC) provides highly competitive funding which currently supports 2 research teams led by top researchers at the University of Tartu, one of them being Professor Teesalu’s team. ERC Starting Grants aim to support up-and-coming research leaders who are about to establish proper research teams and start conducting independent research in Europe.
Copywriter: Marion Jõepera